FDA clears PENS device to treat pain after cardiac surgery

Published On 2022-09-24 04:45 GMT   |   Update On 2022-09-24 09:26 GMT

The US Food and Drug Administration (FDA) has approved Primary Relief, a percutaneous electrical neurostimulation device, to treat pain following cardiac surgery.The wearable, battery-operated device is designed to administer periodic low level electrical pulses to the ear over 72 hours from the activation of the device. The electrical pulses are delivered to branches of the cranial nerves on...

Login or Register to read the full article

The US Food and Drug Administration (FDA) has approved Primary Relief, a percutaneous electrical neurostimulation device, to treat pain following cardiac surgery.

The wearable, battery-operated device is designed to administer periodic low level electrical pulses to the ear over 72 hours from the activation of the device. The electrical pulses are delivered to branches of the cranial nerves on the ear through a wire assembly and stimulation needles.

The percutaneous electrical nerve stimulator (PENS) system can be used for up to three days for symptomatic relief of post-operative pain following cardiac surgery.

"This ground-breaking device allows for significant pain relief without the use of narcotics," said DyAnsys Chief Executive Srini Nageshwar. "By reducing or avoiding the use of opioids after surgery, the risk of addiction is reduced. We look forward to connecting with physicians and patients to make this option available after cardiac surgery among other applications."

Primary Relief also has FDA clearance for use post Cesarean section (C-section) delivery. 

The effectiveness of the device for post-cardiac surgery was demonstrated in a single-centre, double arm, randomized, prospective study involving 60 patients. The analysis showed that minimally invasive nerve stimulation intervention using Primary Relief reduced the pain score compared to a placebo device. It also reduced the requirement for analgesics post surgery.

The mean dosage of fentanyl required as a rescue analgesic in the postoperative period was only one-third of the control group. Only four patients treated with Primary Relief required diclofenac as a second rescue analgesic compared to 19 in the control group.

The nonclinical testing of Primary Relief device included biocompatibility testing, electrical safety (electromagnetic compatibility and safety), performance bench testing and software verification and validation.

DyAnsys also offers two companion PENS devices-First Relief, with FDA clearance for the treatment of diabetic neuropathic pain, and Drug Relief, with FDA clearance as an aid to drug withdrawal.

Tags:    
Advertisement
Article Source : DyAnsys Inc.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News